Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25587240 | 0.85 | — | — | |
| SCHEMBL26152957 | 0.85 | — | — | |
| SCHEMBL823816 | 0.81 | TSHR (0.33) | KIF11POLB | |
| SCHEMBL11955149 | 0.80 | KMT2A (0.35) | AGBL2KIF11KMT2APOLBPKM | |
| SCHEMBL22778748 | 0.78 | P2RX7 (0.37) | P2RX7AGBL2 | |
| SCHEMBL12640236 | 0.77 | TSHR (0.31) | KIF11 | |
| SCHEMBL21316603 | 0.75 | — | — | |
| SCHEMBL12459213 | 0.75 | GABRA1 (0.33) | — | |
| SCHEMBL21265942 | 0.75 | LMNA (0.30) | POLB | |
| SCHEMBL19053356 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230227445-A1 | BENZAMIDE COMPOUND AND USE THEREOF | HUMANWELL HEALTHCARE (GROUP) CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230117403-A1 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC CORPORATION | 2023-04-20 | — | — | US | disclosed |
| US-11214541-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2022-01-04 | — | — | US | disclosed |
| US-20210323916-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2021-10-21 | — | — | US | disclosed |
| US-20210308119-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES | CHEMOCENTRYX, INC. | 2021-10-07 | — | — | US | disclosed |
| US-7932252-B2 | CCR9 chemokine receptor modulators; treating inflammatory and immune diseases; inhibit the binding of chemokines, such as TECK (thymus-expressed chemokine), to the CCR9 receptor; 1-arylsulfonamido-2-aryl(alkyl)benzene compounds | CHEMOCENTRYX, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | P2RX7 174/4885AGBL2 1913/4885KIF11 4825/4885 |
| US-20210308119-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES | CCR9, CCR3, CCR1 | P2RX7 299/4885AGBL2 1384/4885KIF11 2008/4885 |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | AHR, CD274, ARNT | P2RX7 1348/4885AGBL2 885/4885KIF11 4429/4885 |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | P2RX7 7/4885AGBL2 1968/4885KIF11 4684/4885 |
| US-20230227445-A1 | BENZAMIDE COMPOUND AND USE THEREOF | P2RX3, P2RX4, P2RX7 | P2RX7 3/4885AGBL2 2627/4885KIF11 3706/4885 |
| US-11214541-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | CYP19A1, ESR1, GPER1 | P2RX7 961/4885AGBL2 3920/4885KIF11 3392/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | P2RX7 4811/4885AGBL2 1251/4885KIF11 1631/4885 |
| US-20210323916-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, ESR1, ESR2 | P2RX7 976/4885AGBL2 4064/4885KIF11 3633/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | P2RX7 348/4885AGBL2 445/4885KIF11 4645/4885 |
| US-20090163498-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | P2RX7 179/4885AGBL2 1046/4885KIF11 4557/4885 |
| US-20230117403-A1 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | CHRM1, ACHE, CHRM2 | P2RX7 94/4885AGBL2 4005/4885KIF11 4136/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | P2RX7 4802/4885AGBL2 3419/4885KIF11 3553/4885 |
| US-20080161345-A1 | Aryl Sulfonamides | CCR2, CCL2, CX3CR1 | P2RX7 140/4885AGBL2 1500/4885KIF11 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.